The fibroblast growth factors (FGFs) are a group of at least 25 structurally related peptides that are involved in many biological processes. Some FGFs are active in bone, including FGF-1, FGF-2, and FGF-18, and recent evidence indicates that FGF-8 is osteogenic, particularly in mesenchymal stem cells. In the current study, we found that FGF-8 was expressed in rat primary osteoblasts and in osteoblastic UMR-106 and MC3T3-E1 cells. Both FGF-8a and FGF-8b potently stimulated the proliferation of osteoblastic cells, whereas they inhibited the formation of mineralized bone nodules in long-term cultures of osteoblasts and reduced the levels of osteoblast differentiation markers, osteocalcin, and bone sialoprotein. FGF-8a induced the phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) in osteoblastic cells; however, its mitogenic actions were not blocked by either the MAPK kinase (MEK) inhibitor U-0126 or the PI 3-kinase (PI3K) inhibitor LY-294002. Interestingly, FGF-8a, unlike FGF-8b and other members of the family, inhibited osteoclastogenesis in mouse bone marrow cultures, and this was via a receptor activator of NF-B ligand (RANKL)/osteoprotegerin (OPG)-independendent manner. However, FGF-8a did not affect osteoclastogenesis in RAW 264.7 cells (a macrophage cell line devoid of stromal cells) exogenously stimulated by RANKL, nor did it affect mature osteoclast function as assessed in rat calvarial organ cultures and isolated mature osteoclasts. In summary, we have demonstrated that FGF-8 is active in bone cells, stimulating osteoblast proliferation in a MAPK-independent pathway and inhibiting osteoclastogenesis via a RANKL/OPG-independent mechanism. These data suggest that FGF-8 may have a physiological role in bone acting in an autocrine/paracrine manner.
FIBROBLAST GROWTH FACTOR (FGF) signaling pathways have important roles in bone, and mutations of the FGF receptors (FGFRs) have been linked to forms of human dwarfism (40) and craniosynostosis syndromes (37) .
FGF-8 is a secreted protein initially identified from an androgen-dependent mouse mammary carcinoma cell line and is therefore also named androgen-induced growth factor (48) . FGF-8 has been implicated to have a role in skeletal growth and embryonic limb development based on its expression patterns (10, 25, 52) . FGF-8 expression in limb formation models has been found to be induced by FGF-10 (35), although FGF-10 does not affect nonembryonic skeletal cells (42) . FGF-8 stimulates the expression of core-binding factor a-1 (Cbfa1) in the murine fibroblast-derived cell line C3H10T1/2 (55); Cbfa1 is a transcription factor essential for development of osteoblasts. In addition, a recent publication reported that FGF-8 predetermined heterogeneous bone marrow cells to differentiate into osteoblasts (49) . FGF-8 was also found to be mitogenic to MG63 osteosarcoma cells, and there is some evidence that ectopic bone and cartilage form in nude mouse tumors of S115 cells known to produce FGF-8 (49) .
FGF-8, like other FGFs, is highly conserved in evolution, and the FGF-8 gene has eight different isoforms formed by alternative splicing of the mouse gene (28) . The previously reported study in bone marrow cells was performed using FGF-8b (49), whereas we have investigated the actions of FGF-8a compared with FGF-8b in osteoblasts and osteoclasts.
Some FGFs, including FGF-1, FGF-2, and FGF-18, are known to be active in bone. FGF-2 acts directly on osteoblasts by potently stimulating their proliferation, whereas it inhibits bone nodule formation in long-term cultures (39) . FGF-18, which has a high homology to FGF-8 (12, 30) , stimulates the proliferation of primary osteoblasts as well as MC3T3-E1 cells; it does this via the Ras/p42/p44 mitogen-activated protein kinase (MAPK) pathway (42) . FGF-2 and FGF-18 stimulate osteoclast function, inducing osteoclastogenesis via receptor activator of NF-B ligand (RANKL) as well as actively stimulating pit formation (36, 42) . Very recently, FGF-8b and FGF-8e were reported to induce osteoclastic differentiation likely dependent of the RANKL/osteoprotegerin (OPG) pathway (50) .
An earlier report noted that FGF-8a stimulated connexin 43 (Cx43) expression in cultured mesenchymal cells from chicken limb buds (27) . Because Cx43 is a major gap junction protein in osteoblasts (19, 21, 24) , in some instances regulating osteoblast proliferation and differentiation (14, 24, 43) , and Cx43 expression in osteoblastic cells is stimulated when treated by some anabolic factors, such as parathyroid hormone (5, 41), we investigated whether FGF-8 action was indeed mediated by Cx43 in osteoblasts.
In this study, we have determined the effects of FGF-8a on primary osteoblasts as well as in osteoclastic cultures and investigated possible mechanisms of its action. U-18674) coding region inserted in frame with the histidine tag sequence. The FGF-8a protein was purified using Ni-NTA affinity chromatography (Qiagen, Valencia, CA). FGF-8b was purchased from R & D Systems through Pharmaco NZ (Auckland, New Zealand). All bone cell culture media contained 100 units/ml of penicillin and 100 g/ml streptomycin (Invitrogen NZ). Cells were cultured in a humidified atmosphere chamber with 5% CO 2 at 37°C.
MATERIALS AND METHODS

Animals
Osteoblast preparation and proliferation assay. Primary rat osteoblastic cells were prepared from fetal rat calvariae, as described previously (8) . First-passage cells were seeded into 24-well plates at 2.5 ϫ 10 4 cells/well, and proliferation assays were undertaken as described previously (9) . In experiments designed to assess the effects of pharmacological inhibitors of intracellular signaling pathways on the proliferative actions of FGF-8, inhibitor-only controls were included, allowing a comparison of the proliferative effects of FGF-8 in the absence and presence of each inhibitor.
MC3T3-E1 and UMR-106 cells were seeded into 24-well plates at 1.25 ϫ 10 4 and 2.5 ϫ 10 4 cells/well, respectively, and proliferation was measured as above.
Nodule formation assay. As described previously (9) , primary rat osteoblasts were seeded onto 35-mm dishes (3.5 ϫ 10 4 cells ⅐ 3 ml Ϫ1 ⅐ dish Ϫ1 ) in ␣-MEM containing 15% FBS and 50 g/ml Lascorbic acid 2-phosphate. When the cells reached confluence, the medium was replaced and further supplemented with 10 mM ␤-glycerophosphate, and test factors were added. The medium and test factors were changed twice weekly over the 21-day culture period.
Cells were fixed with 10% neutral buffered formalin, washed, and stained using Von Kossa. The mineralized area was imaged and quantified using the program TAS (version 2.05) and Bioquant software (version 7.10.10; Bioquant Image Analysis).
Osteoclastogenesis assays. Osteoclastogenesis was assessed in mouse bone marrow culture, as described previously (6) . Briefly, bone marrow cells were isolated from mouse long bones and incubated for 2 h, and the nonadherent cells were collected and seeded onto 48-well plates. Fresh medium and test substances were added on days 2 and 4 of culture, and 1,25-dihydroxyvitamin D 3 was added on days 0, 2, and 4. Cultures were maintained for 7 days, at which time the cells were fixed, washed, and stained for tartrate-resistant acid phosphatase (TRAP), and positive cells with three or more nuclei were scored as osteoclasts.
RAW 264.7 cells were seeded at 2,000 cells/well in a 48-well plate. Medium was completely replaced 4 h after seeding and on day 2 of culture. RANKL (10 ng/ml; Amgen) and test factors were added at these time points when medium was changed. After culture for 4 to 5 days, cells were fixed and stained for TRAP.
Calvarial organ culture. As described previously (7, 38) , hemicalvariae were isolated from 1-to 3-day-old mice prelabeled with 45 CaCl2 (3 Ci/mouse). The bones were placed on supporting metal grids and preincubated in 0.1% BSA-medium 199 for 24 h. The medium was replaced, and test factors or vehicle were added for 48 h, after which an aliquot of medium was removed and counted for 45 Ca to determine the amount of calcium released from the bones. [ 3 H]thymidine (2 Ci/bone) was then added to the medium and incubated for an additional 4 h. The bones were washed and placed in 5% trichloroacetic acid (TCA) to extract the remaining 45 Ca from the bone, and an aliquot of TCA was taken and counted. The bones were then dried and weighed before being dissolved in KOH and counted for 3 H. Bone resorption was defined as the percentage of 45 Ca in medium total Data are expressed as ratios of treatment to control and presented as means Ϯ SE; n ϭ 6/group. **Significantly different from control (P Ͻ 0.01); ##significantly different from FGF-8a at 100 ng/ml (P Ͻ 0.01). 45 
Ca. [ 3 H]thymidine incorporation was calculated as total counts (dpm) per bone/bone weight (g).
Isolated osteoclast activity assay. As described previously (2, 26), mature osteoclasts were isolated from rat long bones and cultured on bone slices in the presence of FGF-8 for 24 h, at which point the cells were fixed and the number of multinucleated TRAP-positive cells and the number of resorption pits counted. The bone-resorbing activity of the mature osteoclasts was expressed as the ratio of pits per osteoclast.
RNA extraction, RT-PCR, and real-time PCR. Rat brain was collected and stored in RNAlater (Ambion, Austin, TX). Brain tissue acted as a positive control for FGF-8 expression. Osteoblastic cells and bone marrow cells were seeded at 1.5 ϫ 10 5 or 4 ϫ 10 6 cells/well in six-well plates and cultured as described above in proliferation, mineralization, and osteoclastogenesis assays. Cells were harvested on day 3 of culture or otherwise as indicated for RNA preparation using RNeasy Mini Kit and RNase-Free DNase Set (Qiagen) according to the manufacturers' instructions.
First-strand cDNA was synthesized from 2 g of total RNA in a reaction volume of 20 l by random priming and by using Superscript reverse transcriptase (Invitrogen NZ) according to the manufacturer's instructions. Unless otherwise stated, 2.5 l of cDNA was subjected to PCR with reaction profile of 94°C (2 min), 34 cycles of 94 (30 s), 58 (30 s), and 72°C (1 min), and 72°C for 5 min as a final extension step. PCR was carried out with Platinum Tap DNA polymerase (Invitrogen), 1.5 mM MgCl 2, and the appropriate primers at a final concentration of 1 M each in a total volume of 25 l. An aliquot of 5 or 10 l from the PCR reaction was electrophoresed on a 1% agarose gel. The primers for rat total FGF-8 are as follows (amplicon of 374 bp): forward 5Ј-ATGGC AGAAG ACGGA GACC-3Ј, reverse 5Ј-GTGAA GGGCG GGTAG TTGAG-3Ј. The primers used to distinguish among rat FGF-8 isoforms are forward 5Ј-TGCTG TTGCA CTTGC TGGTT CT-3Ј, reverse 5Ј-AGAAC CAGCA AGTGC AA-CAG CA-3Ј.
Real-time PCR reactions were conducted in triplicate in a 96-well or 384-well optical reaction plate (Applied Biosystems, Foster City, CA). VIC-labeled 18S rRNA was used as endogenous control. The primer-probe sets of FAM-labeled mouse or rat osteocalcin, bone sialoprotein, TRAP, calcitonin receptor, OPG, RANKL, FGF-8, and Cx43 were purchased as Assay-on-Demand service. Multiplex PCR was performed by using ABI PRISM 7700 or 7900HT real-time PCR system (Applied Biosystems) with reaction profile of 50 (2 min) and 95°C (10 min) and 40 cycles of 95°C (15 s)/60°C (1 min). All reagents used were from Applied Biosystems.
DNA sequencing. DNA in the band of interest was extracted by using the QIAquick gel extraction kit (Qiagen). DNA sequencing was carried out using an ABI PRISM 3100 sequencer (Applied Biosystems).
Immunohistochemistry of Cx43. Osteoblasts were grown and treated in Lab-Tek chamber slides (Nunc, Naperville, IL), paralleling the proliferation assay above. Immunostaining was performed as described previously (29) . Briefly, cells were washed with PBS, fixed with 4% paraformaldehyde, and permeabilized in 0.01% Triton-PBS. Nonspecific binding sites were blocked with the addition of 10% FBS for 1 h. Cells were incubated overnight at 4°C with monoclonal mouse anti-Cx43 antibody (50 l/well, 1:200 diluted with PBS) and subsequently incubated with secondary fluorescence antibody (50 l/well, 1:200 diluted goat anti-mouse Alexa 568; Molecular Probes) at room temperature for 1 h in darkness. Cells were washed with PBS and then mounted in Citifluor (Alltech Associates, Auckland, New Zealand). The fluorescence images were visualized using a TCS 4D confocal laser-scanning microscope (Leica) at the wavelength of 568 nm.
Western blot. Osteoblastic cells were seeded in six-well plates at a density of 5 ϫ 10 4 cells/ml (3 ml/well) and allowed to grow for 24 h. After serum starvation for 24 h, cells were treated with vehicle or FGF-8 at the indicated concentrations and for the indicated times. The MAPK kinase (MEK) inhibitor U-0126 was added 30 min prior to the FGF-8. The cells were harvested and the whole cell lysates analyzed by immunoblotting, as described previously (15) .
Statistical analysis. Data analysis was performed using t-test or one-way analysis of variance, with post hoc examination of significant main effects using the method of Dunnett. Two-way analysis of variance was used to analyze the data from experiments using inhib- itors of signaling proteins. Data are presented as means Ϯ SE. All tests were two-tailed, and a 5% significance level was maintained throughout these analyses.
RESULTS
FGF-8 stimulates osteoblast proliferation and inhibits osteoblast differentiation.
As shown in Fig. 1 , FGF-8a dosedependently stimulated proliferation of primary rat osteoblasts, UMR-106 cells, and MC3T3-E1 cells, with significant effects seen at 25 ng/ml (0.96 nM) or greater. When the concentration of FGF-8 was increased to 500 ng/ml, proliferation of primary rat osteoblasts was increased ϳ2.2-fold.
To assess the effect of FGF-8 on osteoblast differentiation, longterm bone nodule cultures of rat primary osteoblasts were employed. We found that FGF-8a at 25 and 100 ng/ml significantly reduced nodule formation by 13.2 and 28.6%, respectively (Fig. 2) . FGF-8b was more mitogenic to osteoblasts as well as more potently inhibiting to osteoblast differentiation (mineralization) compared with FGF-8a ( Figs. 1 and 2 ). Visual inspection found that the morphology of osteoblasts was changed by FGF-8b; the cells became spindle shaped, as noted previously in the fibroblast cell line NIH-3T3 by other groups (13, 28) . In addition, real-time PCR results demonstrated that the levels of three osteoblast differentiation markers were also greatly reduced by both isoforms in MC3T3-E1 mineralization cultures, an early marker, RUNX2 (data not shown), and two late markers, osteocalcin and bone sialoprotein (Fig. 2, C and D) .
Osteoblasts express FGF-8. To determine whether FGF-8 is a functional factor in normal physiological processes and whether it acts in a paracrine/autocrine fashion in bone, we determined whether it is expressed in osteoblasts. As shown in Fig. 3 , FGF-8 mRNA was detected in primary rat osteoblasts and in osteoblastic UMR-106 cells. The DNA in this band (374 bp) was extracted and sequenced, which showed that the RT-PCR product was identical to the FGF-8 cDNA sequence (GenBank accession no. AB079113). Real-time PCR results indicated that FGF-8 was expressed at much higher levels in UMR-106 cells than in rat primary osteoblasts. The mRNA level in UMR-106 cells was even higher than that in fetal rat brain. The expression of specific isoforms of FGF-8 was investigated by semiquantitative RT-PCR, using a pair of primers designed to produce different sizes of amplicons for each of the eight potential isoforms. The predicted sizes (bp) of the amplicons are 167 for isoform A, 200 for isoform B, 359 for isoform C, 392 for isoform D, 254 for isoform E, 287 for isoform F, 446 for isoform G, and 479 for isoform H. As shown in Fig. 3C , RT-PCR gave rise to four bands with sizes likely corresponding to isoforms A, B, E, and F in UMR-106 cells and in rat brain.
Previous data have shown the induction of FGF-8 by androgen in the cell line Shionogi carcinoma-3 (48) . Therefore, its expression in osteoblasts, upon androgen treatment, was examined to determine whether FGF-8 is a potential mediator of the anabolic function of androgen in bone. However, real-time PCR results showed that FGF-8 levels were not significantly changed by treatment with either testosterone or dihydrotestosterone at 10 Ϫ8 M (data not shown).
FGF-8 actions on p42/44 MAPK signaling and Cx43 expression in osteoblasts.
These assays were conducted to investigate the mechanisms of FGF-8 actions in osteoblasts. As shown in Fig. 4, A ( Fig. 4C) . However, addition of U-0126 (1 and 10 M) to FGF-8a-treated osteoblastic cells did not prevent the mitogenic effects of the peptide (Fig. 5, A-D) , indicating that the p42/44 MAPK pathway does not subserve the proliferative actions of FGF-8 in osteoblasts. In addition, we also targeted the phospatidylinositol 3-kinase (PI3K) pathway using the PI3K inhibitor LY-294002 (1 M). Again, this inhibitor did not block the proliferative effects of FGF-8 (Fig. 5E ).
In the current study, Cx43 expression was examined by confocal microscopy by immunostaining and real-time PCR. The results from these assays showed no clear difference between the control and FGF-8a treatment (100 ng/ml) for 24 h in primary rat osteoblasts (data not shown). These results were further confirmed by real-time PCR in mineralization cultures of MC3T3-E1 cells at three different time points (0, 7, and 14 days; data not shown).
Effect on osteoclastogenesis and osteoclast activity. FGF-8a inhibited osteoclastogenesis at low concentrations. The results demonstrated that FGF-8a, but not FGF-8b, reduced the number of osteoclasts in the bone marrow culture, with a significant effect seen at concentrations of 0.5-25 ng/ml (Fig. 6, A and B) . At 25 ng/ml, the osteoclast number was reduced by ϳ14%. In addition, we demonstrated by the use of real-time PCR that the osteoclastic markers TRAP and calcitonin receptor were correspondingly reduced by FGF-8a in mouse bone marrow cells (Fig. 6, C and D) . Osteoclastogenesis in RAW 264.7 cells was not altered by FGF-8a at concentrations from 0.05 to 25 ng/ml (Fig. 6E) .
In calvarial organ culture, bone resorption can be measured by 45 Ca release. Fig. 6F shows that FGF-8a at concentrations of 1-100 ng/ml had no significant effect on 45 Ca release in this model. To further assess the effect of FGF-8 on mature osteoclast function, we studied isolated mature osteoclast activity. The results from these experiments showed that the pit formation on bone slices was not altered by FGF-8a at concentrations between 1 and 200 ng/ml (Fig. 6G) . These results indicate that FGF-8 does not act directly on mature osteoclasts to regulate the resorbing activity.
Since RANKL and OPG play key roles in osteoclast development (32), their expression on FGF-8a treatment in primary Fig. 6 . Effects of FGF-8 on osteoclast formation and activity. A and B: effects of FGF-8a and FGF-8b on osteoclast formation in mouse bone marrow cultures. Expression of tartrate-resistant acid phosphatase (TRAP; C) and calcitonin receptor (CTR; D) in bone marrow cells was measured by real-time PCR. FGF-8a showed no effect on osteoclast formation in RAW 264.7 cell culture (E) or on bone-resorbing activity of mature osteoclasts in either mouse calvarial organ culture (F) or rat isolated osteoclast assay (G). Rat amylin (rAmylin) and osteoprotegerin (OPG) are included as controls. Data are expressed as ratios of treatment to control and presented as means Ϯ SE; n ϭ 5-10 (A, B, E, F, and G) or 3/group (C and D) . *P Ͻ 0.05 and **P Ͻ 0.01, significant differences from control. osteoblast cultures was assessed by real-time PCR. Figure 7 demonstrates no significant effect on the RANKL/OPG ratio, indicating that the inhibitory effects of FGF-8 on osteoclast development were not attributable to the modulation of the RANKL/OPG signaling pathway.
DISCUSSION
The role of FGF-8 in fetal organ development, particularly of the limbs, has been well documented (10, 25) . Its expression was detected in the regions of limb outgrowth in early chick and murine embryos (10, 16) . In later embryonic development in the mouse (gestation days E14.5-15.5), FGF-8 is expressed in the dorsal costal cartilage, periosteum, ribs, osteoblast compartment of calvarial bone, mandible, cortical bone, and growth plate of developing long bones (53) . Its expression in craniofacial skeleton of adult zebrafish was only recently documented, and FGF-8 insufficiency in heterozygous mutant zebrafish resulted in craniofacial deformation (1) .
Although evidence suggesting the involvement of FGF-8 on skeletal development has been emerging, FGF-8's role in bone cell biology is poorly understood. Recently, the isoform FGF-8b has been shown to promote osteogenic effects in a mesenchymal stem cell environment, accelerate the development of bone nodule formation in these cells, and have some anabolic effects on cancer-related bone cells (49) . Whereas in our study, using the isoforms FGF-8a and FGF-8b, osteoblast proliferation was stimulated in a nonembryonic primary osteoblast cell culture system, as well as in osteoblastic cell lines, bone nodule formation was decreased in long-term cultures. An earlier study using FGF-8a in chick limb bud development demonstrated that the gap junction protein Cx43 was playing a role in the proliferation was and differentiation in the developing cells, but FGF-8a did not alter Cx43 levels in the current study.
Among the FGF family members whose skeletal actions have been examined, FGF-1, FGF-2, and FGF-18 have been reported to stimulate proliferation of osteoblastic cells (11, 39, 42) . FGF-18, a homolog of FGF-8 (12, 30) , stimulates the proliferation of primary osteoblasts as well as MC3T3-E1 cells via the Ras/MAPK pathway. FGF-18's mitogenic action was blocked by MAPK pathway inhibitors (42) . Our findings also demonstrate that FGF-8a activates p42/44 MAPK signaling in osteoblasts; however, our results argue against involvement of this signaling pathway in its proliferative actions. In addition, we targeted PI3K signaling and also found that this pathway was not involved in FGF-8a's proliferative actions.
Prior to our current study, FGF-8 was known to be expressed only in normal adult tissues in cell types involved in spermatogenesis and oogenesis (51) , although it has been found in various cancer cells (47) . However, we demonstrated that FGF-8 is expressed in osteoblastic cells, similar to FGF-1 and FGF-2 (20, 54) (but not FGF-18), implying possible autocrine/ paracrine effects of FGF-8 in bone cells.
Interestingly, actions on osteoclasts do differ among the FGFs. FGF-2 (18, 34) and FGF-18 (42) induce osteoclastogenesis. In addition, FGF-8 has recently been reported to stimulate osteoclast formation in cocultures of mouse bone marrow cells, with MDA-MB-231 breast cancer cells transfected with FGF-8b and FGF-8e on bovine cortical bone slices (50) .
In contrast, in the current study we have investigated FGF-8's action in a similar bone marrow culture system stimulated with 1,25-dihydroxyvitamin D 3 , and FGF-8a consistently downregulated osteoclastogenesis, whereas FGF-8b had no effect. On the other hand, FGF-8a had no effect on osteoclastogenesis in RAW 264.7 cells exogenously stimulated by RANKL, suggesting that FGF-8a acts indirectly via osteoblastic stromal cells rather than directly on preosteoclasts. FGF-8's inhibition of bone resorption did not extend to mature osteoclast activity, as evidenced by experiments performed both in calvarial organ culture and with the use of isolated osteoclasts. In contrast, FGF-2 and FGF-18 stimulated mature osteoclast activity (3, 22, 42) .
Many osteotropic and osteolytic agents known to have an impact on osteoclast development and bone resorption have been found to exert their effects through the mediation of RANKL/OPG (31-33). FGF-2 and FGF-18 stimulate osteoclast function, inducing osteoclastogenesis via RANKL as well as actively stimulating pit formation (36, 42) . FGF-8b and FGF-8e's osteoclastic regulation is also reported to be likely dependent of the RANKL/OPG pathway (50) . However, our data, which demonstrate no change in the RANKL/OPG ratio following FGF-8a treatment of rat primary osteoblasts, suggest that FGF-8a inhibits osteoclastogenesis by an alternate mechanism. Evidence supporting the existence of an alternate pathway(s) in osteoclastogenesis has been accumulating in the last couple of years from studies of other osteotropic agents such as TNF␣, IL-1, peptidoglycan, and lipopolysaccharide (17, 23, 44) .
The lack of any direct effect of FGF-8 on RAW 264.7 cells and mature osteoclast activity suggests the absence of the functioning receptor for FGF-8 in these cells. Indeed, it is generally recognized that FGF-8 interacts preferentially with FGFR4 and, to a lesser extent, with FGFR3 and FGFR2 (36, 46) . Although these receptors are expressed in osteoblasts, they are not expressed in the isolated osteoclasts. The only FGF receptor expressed in osteoclasts is FGFR1 (3), which shows little specific binding with FGF-8 (36, 46) . Similar FGFR expression pattern may apply to osteoclast precursors (4) . In this regard, FGF-8 is different from FGF-2, which interacts with FGFR1 (36, 46) . In summary, our results are the first to demonstrate the stimulatory effects of FGF-8 on osteoblast proliferation in primary osteoblast cultures and that osteoblast nodule formation was inhibited in long-term cultures of osteoblasts. We have also shown that neither Cx43 nor the ERK and PI3K signaling pathways are involved in these effects of FGF-8a on osteoblasts. We have also been the first to demonstrate that FGF-8a downregulates osteoclastogenesis in a stromal celldependent manner but in a manner independent of RANKL/ OPG. However, FGF-8 does not have an effect on the mature osteoclast activity. Importantly, we have also found that FGF-8 is produced in the bone microenvironment, suggesting a role for FGF-8 in normal bone metabolism where the bone cells are acting in an autocrine/paracrine manner. FGF-8 may play a role in the regulation of bone remodeling by uncoupling the actions of osteoblasts and osteoclasts. However, because FGF-8-knockout mice die before skeletal development (36, 45) , it has been difficult to ascertain the effects of FGF-8 in bone metabolism. In light of these results, it would be interesting to observe the effects of a conditional knockout of FGF-8 in bone.
